ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

Current Report (Form 8-K | Period ending 2024-11-18)

Current Report (Form 8-K | Period ending 2024-11-06)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Acadia Pharmaceuticals (ACAD US)

Current Report (Form 8-K | Period ending 2024-11-18)

Current Report (Form 8-K | Period ending 2024-11-06)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Current Report (Form 8-K | Period ending 2024-09-17)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)